Inhibrx Biosciences Inc. (INBX)
Inhibrx Biosciences Statistics
Share Statistics
Inhibrx Biosciences has 14.48M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 14.48M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 72.16% |
| Shares Floating | 10.04M |
| Failed to Deliver (FTD) Shares | 1.29K |
| FTD / Avg. Volume | 1.15% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 0.14 and the forward PE ratio is -1.51. Inhibrx Biosciences's PEG ratio is 0.
| PE Ratio | 0.14 |
| Forward PE | -1.51 |
| PS Ratio | 1139.75 |
| Forward PS | 0.8 |
| PB Ratio | 1.71 |
| P/FCF Ratio | -1.16 |
| PEG Ratio | 0 |
Enterprise Valuation
Inhibrx Biosciences has an Enterprise Value (EV) of 83.4M.
| EV / Sales | 417.01 |
| EV / EBITDA | 0.05 |
| EV / EBIT | -0.43 |
| EV / FCF | -0.42 |
Financial Position
The company has a current ratio of 3.94, with a Debt / Equity ratio of 0.06.
| Current Ratio | 3.94 |
| Quick Ratio | 3.94 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0 |
| Debt / FCF | -0.04 |
| Interest Coverage | -24.57 |
Financial Efficiency
Return on Equity is 1263.3% and Return on Invested Capital is -234.02%.
| Return on Equity | 1263.3% |
| Return on Assets | 933.56% |
| Return on Invested Capital | -234.02% |
| Revenue Per Employee | $1.28K |
| Profits Per Employee | $10.82M |
| Employee Count | 156 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 2K |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -65.13% in the last 52 weeks. The beta is -1.09, so Inhibrx Biosciences's price volatility has been lower than the market average.
| Beta | -1.09 |
| 52-Week Price Change | -65.13% |
| 50-Day Moving Average | 13.12 |
| 200-Day Moving Average | 14.16 |
| Relative Strength Index (RSI) | 41.06 |
| Average Volume (20 Days) | 112.42K |
Income Statement
In the last 12 months, Inhibrx Biosciences had revenue of 200K and earned 1.69B in profits. Earnings per share was 114.01.
| Revenue | 200K |
| Gross Profit | 200K |
| Operating Income | -331.45M |
| Net Income | 1.69B |
| EBITDA | 1.7B |
| EBIT | 1.7B |
| Earnings Per Share (EPS) | 114.01 |
Balance Sheet
The company has 152.6M in cash and 8.05M in debt, giving a net cash position of 144.55M.
| Cash & Cash Equivalents | 152.6M |
| Total Debt | 8.05M |
| Net Cash | 144.55M |
| Retained Earnings | -106.13M |
| Total Assets | 180.77M |
| Working Capital | 119.67M |
Cash Flow
In the last 12 months, operating cash flow was -194.41M and capital expenditures -2.6M, giving a free cash flow of -197.01M.
| Operating Cash Flow | -194.41M |
| Capital Expenditures | -2.6M |
| Free Cash Flow | -197.01M |
| FCF Per Share | -13.31 |
Margins
Gross margin is 100%, with operating and profit margins of -165724% and 843786%.
| Gross Margin | 100% |
| Operating Margin | -165724% |
| Pretax Margin | 843787% |
| Profit Margin | 843786% |
| EBITDA Margin | 851675% |
| EBIT Margin | -165724% |
| FCF Margin | -98503% |
Dividends & Yields
INBX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 740.32% |
| FCF Yield | -86.42% |
Analyst Forecast
Currently there are no analyst rating for INBX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 33.08 |
| Piotroski F-Score | 5 |